14 / 54 = 26%. I think my calculator is working correctly. $PDSB

If I’m reading/interpreting the $PDSB press release this morning correctly (oh lord… ducks), the “new” confirmed ORR for the PDS0101/Keytruda trial is 26%. 14/54 That’s on the low end of the possible range, and not much different from Keytruda alone.

Muzzled for years, vindicated MIT professor says fraud investigation into his lab did lasting damage Remember when Tillman Gerngross accused Ram Sasisekharan of scientific fraud? Turns out, Ram was innocent. Science karma ensued. By @damiangarde

Biogen’s $BIIB boardroom scandal saddles CEO with first crisis A follow-up story on the Denner-Langer board controversy from @damiangarde and me.

EXCLUSIVE --> Biotech executive nominated to Biogen $BIIB board is mother of director’s child, records show We have previously unreported details about Alex Denner's exit from Biogen's board and the nomination of his romantic partner, Susan Langer

Downtown San Francisco’s obituary. Some of my SF friends tell me it doesn’t matter bc “who goes downtown, anyway?” #JPM24 will be interesting.

Read the entire Laronde story. With dogged, meticulous reporting, Allison DeAngelis @ADeAngelis_bio goes deep inside Laronde — ripping the rosy facade off one of Flagship's most-hyped startups. Fantastic journalism.

Laronde was founded to development a new class of drugs based on "endless RNA." But as STAT reports exclusively, soon after a $400M Series B round, some staffers started to question foundational preclinical research. The data were too perfect and could not be replicated.

Laronde blamed a single scientist for producing the suspect data. She quietly left the company. But other staffers say pressure to produce "positive" data was intense. Executives dismissed problems, ignored concerns while pitching Laronde's vision to outside investors.

Top-notch reporting by my STAT @ADeAngelis_bio Laronde, a Flagship upstart hailed as "Moderna 2.0," has been roiled by a data integrity issue that forced it to shelve lead drug programs. Dozens of employees have left, including top execs.

Novartis $NVS to buy Chinook Therapeutics $KDNY, developer of kidney disease therapies, in $3.2 billion deal via @DrewQJoseph

Kura Oncology $KURA highlights leukemia remission data as it enrolls larger trial via @DrewQJoseph #EHA23

Please, Inter. Do this. 🙏

Chamber of Commerce tries new legal arguments to challenge Medicare drug-price negotiation via @rachelcohrs

That’s more bathroom reading material than most guys need.

A bathroom chandelier. 💪🏻

FDA panel unanimously endorses Eisai’s Alzheimer’s drug via @statnews

Latest from the FDA’s Leqembi panel: Do the results of Study 301 (CLARITY AD) verify the clinical benefit of lecanemab for the treatment of AD? Yes 6 No 0 That’s the only voting question. Discussion of patient subgroups is next. $ESALY $BIIB #Alzheimers

The sun rises in the east, sets in the west… and Diane Zuckerman testifies against a drug approval at an adcomm.

Public hearing underway. Tracking the FDA advisory panel on Eisai and Biogen’s treatment for Alzheimer’s disease

Celebrity biostatistician Tristan Massie can’t get his mic to work. This is the most fun we’ve had today during the Leqembi FDA panel.